Conditions: Healthy Participants
Allocation: RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 38
Healthy volunteers: yes

Brief summary:
The main purpose of this study is to evaluate the safety and how well the body will handle a single dose of increasing strength of study drug LY3050258. Each participant will receive LY3050258 or placebo once, in each of 2 dosing periods. At least 7 days will pass between doses. This study will last approximately 45 days for each participant. Screening is required within 28 days before the start of the study.

Detailed description:

Arms:
arm 1: Single escalating dose of LY3050258 (2 milligram \[mg\] up to 200 mg) administered in up to two of two periods. arm 2: Single dose of placebo matching LY3050258 administered in up to one of two periods.

Interventions: intervention 1: LY3050258 intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: